As previously announced, Phanes is conducting this study under a clinical supply agreement with Roche. Peluntamig is Phanes' first-in-class native IgG-like bispecific antibody (bsAb) targeting ...

SAN DIEGO, May 5, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that ...